Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO’s platform for worldwide gene therapy commercialization CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO (NASDAQ: AVRO) (the “Company”), a...
BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today unveiled its latest solution for decentralized clinical trials from Covance to help transform the conduct...
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the clinical trial independent Data Safety Monitoring Board (DSMB) has...
STOCKHOLM, Dec. 19, 2019 /PRNewswire/ — Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that 198 out of a total of 200 patients required for Part A of the Company’s pivotal Phase 3 study NefIgArd, have been randomized. Top line...
BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that, following a strategic...
Email
Text